Startup Glycomine Lands $115M for Clinical Trial in Ultra-Rare Disease With No Approved Drugs

Startup Glycomine Lands $115M for Clinical Trial in Ultra-Rare Disease With No Approved Drugs

Glycomine’s lead program is an experimental treatment for PMM2-CDG, an ultra-rare enzyme deficiency often misdiagnosed as cerebral palsy. With encouraging results from an open-label Phase 2 study, the biotech startup is now preparing for a placebo-controlled test that could potentially support a regulatory submission. The post Startup Glycomine Lands $115M for Clinical Trial in Ultra-Rare Disease With No Approved Drugs appeared first on MedCity …

Startup Glycomine raises $115M to push rare disease drug deeper into testing

The biotech is developing an experimental drug for the most common of a family of disorders all caused by errors in glycosylation.

Glycomine secures $115m funding for Phase IIb trial of rare disease drug

The funding round was spearheaded by CTI Life Sciences Fund, Advent Life Sciences, and abrdn-managed funds. Current investors, including Sanofi Ventures, Novo Holdings, RiverVest Venture Partners, Sanderling Ventures, The post Glycomine secures $115m funding for Phase IIb trial of rare disease drug appeared first on Pharmaceutical Business review.

Glycomine Raises $115M for Phase IIb of Genetic Glycosylation Disorder Drug

At a time when securing substantial funding requires a needle through a shrinking hole, Glycomine is passed through and off to the sewing machine. The San Francisco-based company recently closed a $115 million financing round, positioning itself as a frontrunner in the fight against rare diseases, specifically, congenital disorders of glycosylation (CDGs). The financing will help get Glycomine’s lead program, GLM101, a groundbreaking treatment f…

Glycomine raises $115m to advance rare disease therapy into Phase IIb

Glycomine’s Series C raise highlights investor confidence in the company amid pressure on the paediatric rare disease sector.The post Glycomine raises $115m to advance rare disease therapy into Phase IIb appeared first on Clinical Trials Arena.

Glycomine raises $115m to advance rare disease therapy into Phase IIb - Pharmaceutical Technology

Glycomine’s Series C raise highlights investor confidence in the company amid pressure on the paediatric rare disease sector.